Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure
NCT00575419
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class
Stopped
Low accrual
Conditions
Contrast Induced Nephropathy
Interventions
DRUG:
N-acetylcysteine
Sponsor
Oregon Health and Science University